Ocular Therapeutix: Considering Their Phase 3 'Superiority' Trial's Prospect [Seeking Alpha]
Ocular Therapeutix, Inc. (OCUL)
Last ocular therapeutix, inc. earnings: 3/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ocutx.com
Company Research
Source: Seeking Alpha
Current wet AMD treatment is dominated by anti-VEGF drugs, with EYLEA (2 mg) holding a 63% global market share in 2024. I take a close look at their phase 3 "superiority" trial, SOL-1, for wet AMD and share my thoughts here. Klaus Vedfelt/DigitalVision via Getty Images Ocular Therapeutix ( OCUL ) is a commercial-stage biotech that focuses on retinal disease, one of the leading causes of blindness. Their lead candidate, AXPAXLI, also known as OTX-TKI, is being studied for wet (neovascular) age-related macular degeneration, or wet AMD. This article was written by Analyst's Disclosure: I/we have a beneficial short position in the shares of OCUL either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. I long 2028 $30 put. Seeking Alpha's Disclosu
Show less
Read more
Impact Snapshot
Event Time:
OCUL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCUL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCUL alerts
High impacting Ocular Therapeutix, Inc. news events
Weekly update
A roundup of the hottest topics
OCUL
News
- Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026GlobeNewswire
- Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Ocular Therapeutix (NASDAQ:OCUL) Misses Q4 CY2025 Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Ocular Therapeutix's Recent Stock Weakness Presents Buying Opportunity, RBC Says [Yahoo! Finance]Yahoo! Finance
- Ocular Therapeutix (NASDAQ:OCUL) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.MarketBeat
OCUL
Earnings
- 11/4/25 - Beat
OCUL
Sec Filings
- 2/12/26 - Form 144
- 2/12/26 - Form 144
- 2/12/26 - Form 144
- OCUL's page on the SEC website